Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Deals are abound!!!!

<< Previous

Bullboard Posts

Next >>

Comment by askretkaon Aug 05, 2022 11:40am

172 Views

Post# 34874244

RE:Deals are abound!!!!

It's interesting that Roche has 1. very good Pancreatic data with Pelareorep/ Tecentriq. -------------------------- 2. In June got first approval ever for Roche's Lunsumio is the first CD20xCD3 bispecific antibody approved anywhere. ---------------------------- 3. Roche is extending its reach in cancer cell therapy,announcingon Wednesday a new deal to develop off-the-shelf treatments with the help of Poseida Therapeutics. --------------------------------------- 3 things that happened in recent months that would line up nicely with pelareorep combos. Cheers!!!!!

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario